BLAINJECTIONINJECTABLE
Approved
Dec 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZORBTIVE (somatropin recombinant) is a recombinant human growth hormone administered by injection. It is indicated for patients with short bowel syndrome to improve intestinal absorption and reduce dependence on parenteral support. The drug works by stimulating growth and metabolic processes to enhance nutrient uptake in compromised GI systems.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), suggesting a stable but consolidating commercial team focused on retention and operational efficiency.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZORBTIVE offers deep expertise in rare disease and specialty pharmacy dynamics, but limited job openings reflect its mature status. Career progression typically involves mastery of complex reimbursement, provider relationships, and patient support programs in niche markets.
Medical Science LiaisonBrand Manager
Worked on ZORBTIVE at EMD Serono Research & Development Institute, Inc.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.